https://www.selleckchem.com/pr....oducts/brefeldin-a.h
9%. More than 90% of patients were able to tolerate and complete the HD-MTX. The incidence of ≥ grade 3 hematologic and non-hematologic toxicities were 4.8% and 17.1%, respectively. Treatment-related mortality rate was 2.4%. There was no difference in toxicity between patients with age 60 and ≥ 60years. At the median follow-up duration of 39.8months, the median PFS was 35.2months (95% CI 12.4-69.3) and median OS was 46.5months (95% CI 21.8-NR). High-dose methotrexate followed by consolidation whole-brain radiotherapy and cytara
Gefällt mir
Kommentar
Teilen
